MedPath

Intralesional Cryotherapy With a Argon Gas Based Device for the Treatment of Keloid and Hypertrophic Scars

Not Applicable
Completed
Conditions
Keloid
Cicatrix
Hypertrophic
Interventions
Procedure: Intralesional cryotherapy
Registration Number
NCT02063243
Lead Sponsor
Amsterdam UMC, location VUmc
Brief Summary

This prospective evaluation studies the effectiveness of Intralesional (IL) cryotherapy with a argon gas based device in treating keloids and hypertrophic scars in population consisting of all Fitzpatrick skin type patients

Detailed Description

Intralesional (IL) cryotherapy is a novel treatment for keloids and hypertrophic scars, in which the scar is frozen from inside. Published results are promising, however only Caucasian patient populations have been studied. This prospective evaluation studies the effectiveness of IL cryotherapy in treating keloids and hypertrophic scars in a population consisting of all Fitzpatrick skin type patients.

Multiple devices are available, mostly based on a simple open system. Closed, argon gas based, systems are highly controlled and provide accurate freezing. However, this technique has never been used for IL cryotherapy for the treatment of keloid or hypertrophic scars. All patients with keloid or hypertrophic scars meeting inclusion criteria were treated with a argon based device called Seednet. Scar quality and possible recurrence are assessed pre- and postsurgery (3, 6 and 12 months) with objective devices determine scar color, scar elasticity, scar volume and patient's skin type. In addition, scars are evaluated using the Patient and Observer Scar Assessment Scale.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria
  • Keloids, defined as excessive scar tissue raised above skin level and proliferating beyond the confines of the original lesion
  • Hypertrophic scars1 older than 12 months and insensitive to other treatments. Keloids were distinguished from hypertrophic scars based on the clinical judgment of experienced plastic surgeons and on the age of the scar (>1yr)
  • A period between previous treatment and IL cryotherapy covered a minimum of 12 weeks
  • Patients with all Fitzpatrick17 skin types
  • Patients older than 10 years of age
Exclusion Criteria
  • pregnancy
  • diabetes mellitus

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
keloid or hypertrophic scarsIntralesional cryotherapyAll patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
Primary Outcome Measures
NameTimeMethod
Recurrence0-12 months

Judgment of recurrence, defined as a growing, pruritic, nodular scar

Secondary Outcome Measures
NameTimeMethod
Scar elasticity0-12months

Scar elasticity, measured in two parameters: extension and elasticity

Trial Locations

Locations (1)

VUmc

🇳🇱

Amsterdam, Noord-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath